PMC:3492202 / 9887-11210 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3492202","sourcedb":"PMC","sourceid":"3492202","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3492202","text":"There are several possibilities to account for the failure in detecting neutralizing antibodies. In general, bats seem to produce lower level of neutralizing antibodies in response to viral infection, possibly due to the lower affinity of the bat antibodies [14]. Alternatively, it is possible that one or more as-yet-unknown ebolaviruses are circulating among the bat populations sampled in this study, producing antibodies cross-reactive with, but not neutralizing EBOV or RESTV. Also, a new ebolavirus species closely-related with EBOV but not the RESTV might be missed during the initial screening using Reston-NP solely. An initial screening for eboalvirus antibodies should be conducted by using ELISA with a 1:1 mixture of recombinant NP of EBOV and RESTV to detect wider range of ebolavirus species. Recently, a genetically distinct filovirus was found in dead insectivorous bats in Spain [15], suggesting that filoviruses have a wider host range and geographical location than previously thought. The unsuccessful identification of ebolavirus-related genes in the samples is likely attributable to the often low-level of virus replication, the similarly transient nature of the infection in bats or the sequence mis-match of the PCR primers used and the target sequence of the potential unknown ebolavirus genomes.","tracks":[{"project":"2_test","denotations":[{"id":"23062147-20162414-143781709","span":{"begin":259,"end":261},"obj":"20162414"},{"id":"23062147-22039362-143781710","span":{"begin":898,"end":900},"obj":"22039362"}],"attributes":[{"subj":"23062147-20162414-143781709","pred":"source","obj":"2_test"},{"subj":"23062147-22039362-143781710","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#a8ec93","default":true}]}]}}